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Key points/Summary: 
• HCV reinfection incidence rates among HIV-infected men who have 
sex with men (MSM) range from 3-15 per 100 person-years. These 
rates are 3-10 times higher than baseline incidence.  
• As settings strive to meet the World Health Organization elimination 
targets, concerns surround the high reinfection in this population.  
Modeling indicates that tackling increasing incidence and high 
reinfection requires widespread HCV treatment combined with 
behavioral interventions.  
• Behavioral interventions studies addressing HCV reinfection are 
required, such as the ongoing HCVree trial in Switzerland targeting 
MSM who engage in inconsistent condom use.  
• Other interventions may include traditional harm reduction 
interventions, adapted behavioral interventions targeting HIV risks 
among substance using populations, and interventions to prevent risk 
related to substance use with sex.  
 
Introduction 
Among people living with HIV worldwide, it has been estimated that 2.4% 
(IQR 0.8 – 5.8) are coinfected with hepatitis C virus (HCV), yet this rises to 
6.4% (IQR 3.2 – 10.0) among men who have sex with men (MSM)1. Indeed, 
an epidemic of HCV among HIV-infected (HIV+) men who have sex with men 
(MSM) has been documented in major urban centers in the United States, 
Europe, and Australia, with dramatic increases in HCV incidence and/or 
prevalence in the past decade2-10. This epidemic has been associated not 
only with injection drug use (IDU), but also with high-risk sexual practices and 
substance use with sex among those with no history of IDU11. As HIV+ 
individuals are living longer in the era of highly active antiretoriviral therapies, 
the morbidity and mortality associated with viral hepatitis coinfection 
increases. Consequently, liver-related mortality is one of the leading non-
AIDS causes of death among HIV+ individuals12. 
 
The World Health Organization recently released targets for HBV and HCV 
elimination, which included a 90% relative reduction in new infections and a 
65% relative reduction in hepatitis-related mortality by 203013. As a result, 
policymakers are looking for evidence-based preventions strategies to 
achieve these targets. Recent advanced in HCV direct-acting antiviral 
therapies (DAAs) have resulted in short-term (8-12 week), all-oral, highly 
tolerable treatments with cure rates in excess of 90% for both HCV 
moninfected and HIV/HCV coinfected individuals alike14. This has led to 
substantial optimism that expansion of HCV treatment could both lead to 
individual cure and also potential prevention of onwards transmission15. 
However, due to the high cost of HCV therapy, concerns regarding reinfection 
continue to hamper efforts to scale-up HCV treatment for those at risk of 
transmission such as MSM and people who inject drugs.  
 
In this paper we discuss the empirical evidence surrounding HCV reinfection 
among MSM, modeling evidence of the importance of reinfection on achieving 
HCV elimination, and potential strategies to reduce reinfection.  
 
HCV reinfection among MSM: epidemiological evidence 
Reinfection with HCV following treatment or spontaneous clearance has been 
demonstrated in animal models, people who inject drugs and more recently 
among HIV+ MSM16. Indeed, several studies in the pre-DAA era have 
demonstrated that the reinfection incidence among HIV+ MSM in Western 
Europe and the U.S. is alarmingly high - approximately 3-10 times the 
baseline incidence in this population17-20. A summary of studies of reinfection 
incidence rates following successful treatment is shown in Figure 1.  
 
The first of these studies, performed in Amsterdam, retrospectively identified 
56 HIV+ MSM who had been successfully treated for acute HCV between 
2003 and 2011 18. There were 11 confirmed reinfections using phylogenetic 
analysis of the E2/HVR region of the virus, yielding a reinfection incidence of 
15.2 per 100 person-years (/100py) (95% CI 8.0-26.5). This reinfection 
incidence was approximately 10 times the primary HCV infection incidence 
among HIV+ MSM in Amsterdam 21. The authors also found that for 
individuals who had behavioral data, those that underwent reinfection were 
more likely to report non-injecting recreational drug use than those that did not 
undergo reinfection. 
 
In London, a retrospective cohort study from 2004-2012 examined HCV 
reinfection incidence following both successful treatment and spontaneous 
clearance of HCV infection 19. Among 191 patients who were either treated for 
HCV infection or who spontaneously cleared their infection, 44 reinfections 
occurred, representing an incidence of 7.8/100py (95%CI 5.8-10.5). This 
reinfection rate is 6-7 times the observed primary incidence among HIV+ 
MSM in the UK (1.02-1.38 per 100py) 22. Interestingly the authors found 
indication of a higher reinfection rate among those treated for HCV 
(9.6/100py, 95%CI 6.6-14.1) than among those who spontaneously cleared 
their infection (4.2/100py, 95%CI 1.7-10) though the difference did not reach 
significance. The authors hypothesized that this may be due to a degree of 
protective immunity developed among individuals who spontaneously clear 
their infection making it less likely they become reinfected or that if any 
reinfection occurred it was spontaneously cleared. 
 
In a larger multicenter study between 2002-2014 including eight hospitals 
across Austria, France, Germany and the UK from the European AIDS 
Treatment Network (NEAT), nearly a third of HIV+ MSM were reinfected with 
HCV within 5 years of clearing their primary infection either through 
successful treatment or spontaneous clearance 17. Among 606 HIV+ MSM 
who cleared their primary infections, 143 were reinfected, with an overall 
reinfection incidence of 7.3/100py (95%CI 6.2-8.6) 17. The reinfection 
incidence per center is shown in Table 1. As in the London study, a trend for 
lower reinfection incidence following spontaneous clearance of the initial HCV 
infection when compared to those that were successfully treated was 
observed (HR 0.62, 95%CI 0.38-1.02, p=0.06). Individuals who spontaneously 
cleared their initial infection were more likely to spontaneously clear any 
reinfection, supporting the possibility of protective immunity or favorable host 
defenses such as the IL28B CC genotype. The authors additionally found that 
the incidence of a second reinfection (18.8/100py, 95%CI 12.9-27.5) was 
higher compared to the incidence of first reinfection (HR 2.5, 95%CI 1.7-3.8), 
suggesting that the HCV epidemic may in part be being driven by a small 
group of high-risk individuals.  
 
Outside Europe but still during the pre-DAA era, one recent retrospective 
study in San Diego, California found that among 43 HIV+ MSM who had been 
successfully treated for their HCV infection between 2008 and 2015, 3 
became reinfected yielding a reinfection incidence of 2.9/100py (95% CI 0.6-
8.4) 20. This compared to a local primary incidence of 1.2/100py (95%CI 1.0-
1.4), indicating that reinfection rates may be 2-3 fold that of primary infection.  
 
The studies discussed above were performed in the period that prolonged 
interferon containing regimens were the standard of care. Given the shorter 
courses and much greater tolerability of DAA therapy, concerns have arisen 
that improved therapy may lead to an increase in risk taking behavior and 
higher reinfection incidence. One study to date has examined HCV reinfection 
in the DAA era. This was an analysis of the German hepatitis C cohort 
(GECCO) looking at HCV reinfection following DAA therapy between 2014-
2016, finding that among 175 HIV+ MSM treated between February 2014 and 
May 2016, 7.4% (13/175) were reinfected 23. Further work examining 
reinfection incidence rates in the DAA era will shed important light on this 
issue. 
 
No studies have identified behavioral risks specifically associated with HCV 
reinfection among HIV+MSM. However, numerous studies have explored risk 
behaviors associated with HCV prevalence and incidence in this population, 
showing that fisting24-28, rectal trauma with bleeding28, condomless receptive 
anal intercourse (AI)24, 29, 30, group sex24, 28, 29, injecting drug use (IDU)25, 29, 
sex while high on methamphetamine 30, consumption of gamma 
hydroxbutyrate (GHB)25, recreational use of cocaine, ecstasy, GHB, ketamine, 
amphetamine, or methamphetamine before or during sexual contact27 are 
associated with HCV acquisition. Interventions aimed at reducing risk of HCV 
infection/reinfection should therefore target these associated risks. 
 
Modeling the impact of reinfection on achieving HCV elimination among 
PWID versus MSM populations 
A number of theoretical epidemic modeling studies have evaluated the 
potential impact of scaled-up of HCV prevention on HCV prevalence and 
incidence among people who inject drugs, including the risk of reinfection. 
Empirical studies have shown that HCV reinfection rates among PWID are 
low (3% per year in the IFN-containing era)31. Unfortunately few studies have 
directly compared HCV primary incidence and reinfection rates among PWID 
in the same setting, but the reported rates are broadly similar to, if not lower 
than primary incidence rates. As a conservative assumption, the vast majority 
of epidemic models have assumed that the risk of reinfection is equal to 
primary infection, and have studied settings with varied incidence from 3%-
30% per year, in North America, Europe, Asia, and Australia32-36. In general, 
these studies have found that despite the risk of reinfection, HCV incidence 
and prevalence can be dramatically reduced (in many settings by 90% by 
2030) with scaled-up HCV treatment to rates to below 100 per 1000 PWID 
annually, particularly in combination with harm reduction. As such, relatively 
modest levels of treatment are required to eliminate HCV despite this risk of 
reinfection. 
 
Despite this encouraging evidence, a few recent epidemic modeling analyses 
have shown that achieving substantial reductions in HCV incidence among 
HIV+ MSM populations is likely to be more challenging compared to among 
PWID due to relatively high rates of existing HCV treatment combined with 
elevated risk of reinfection (indicating a high risk core group) and increasing 
incidence over time in many settings such as Switzerland and Berlin 37-39. 
Existing modeling studies have focused on the UK, Switzerland, Berlin, and 
the Netherlands, showing that achieving >80% reduction in incidence requires 
treating virtually all MSM upon diagnosis combined with risk reduction to 
prevent infection/reinfection. In the UK, a modeling study indicated that 
scaled-up rates of DAA therapy (from 46% to 80% treated within a year of 
diagnosis and from 7%/year to 20%/year thereafter) could reduce incidence 
among HIV+ MSM over 60% by 2030, but could not meet elimination 
targets37, thus likely requiring additional behavioral interventions. Similar 
modeling findings in Switzerland prompted the generation of a behavioral 
intervention among MSM, described below.  
 
The Swiss HCVree behavioral intervention trial and epidemic modeling 
 
Since the mid 2000’s, an outbreak of incident HCV infections among HIV+ 
MSM became evident in Switzerland 10, 40. This new epidemic co-occurred 
with a rise in self-reported condomless sex with occasional partners in this 
population 10. Men who have sex with men accounted for 24% and 85% of all 
incident HCV infections in the Swiss HIV Cohort Study (SHCS, www.shcs.ch) 
before and after 2006 respectively 41.  The health care system responded with 
a 10-fold increase in HCV treatment rate 10, 38. Rising treatment rates 
coincided with increased awareness of this epidemic and the advent of better 
treatments, namely DAA 42. But such increases in treatment rate did not result 
in reduced HCV incidence among HIV+ MSM. Due to the high costs of these 
drugs 43, reimbursement in Switzerland was initially restricted to people who 
had reached advanced stages of liber fibrosis. This inhibited early treatment 
of incident infections with DAAs outside clinical trials.  
    
Treatment reimbursement restrictions were however not the only barrier to 
tackle the rising epidemic. A model of HCV transmission among HIV+ MSM 
was developed and calibrated to Switzerland and projected the effect of 
treatment interventions assuming different scenarios of risk behavior. The 
model suggested that high rates of DAA-based treatment may fail at reducing 
HCV primary and reinfection incidence if sexual practices associated with 
transmission continue to rise among the MSM population, but could lead to 
declining incidence if the frequency of such practices stabilizes. Moreover, the 
model projected that in 2030 57% of all infections would be reinfections if risk 
behavior rises and 23% if risk behavior stabilizes 38. 
 
Given these projections and the limitations imposed by regulatory 
reimbursement restrictions, clinicians from the SHCS engaged in a 1-year 
clinical trial that provided early treatment for HCV infections in MSM and 
prevented reinfections through risk counselling. The study includes three 
phases: First, all MSM were screened for replicating HCV infection with HCV 
RNA; second, all participants infected with HCV genotypes 1 or 4 were 
offered treatment with grazoprevir/elbasvir ±ribavirin; and third, HCV RNA 
screening will be repeated in all MSM to assess the effect of this intervention 
on HCV prevalence. The study started in October 2015 with the screening of 
4 257 MSM 44. One hundred and seventy eight (4.8%) had a replicating HCV 
infection. Of those, 94% were infected with HCV genotypes 1 or 4 and were 
offered treatment with the study drugs. The evaluation of the treatment phase 
and the subsequent re-screening phase is currently ongoing. In addition to 
HCV treatment, enrolled patients who reported inconsistent condom use with 
occasional partners received four 45-minute sessions of individual sexual risk 
counseling at weeks 4, 6, 8, and 12. This behavioral intervention which was 
specifically developed for this patient group included detailed interviews and 
computer-assisted counselling similar to a previous European Multi-center 
study targeting HIV positive MSM 45. 
 Salazar-Vizcaya et al. subsequently used epidemic modeling to predict the 
potential impact of the Swiss HCVree trial in order to assess the potential of 
this type of (short-term) treatment plus intensive intervention counseling. 
Simulations considered intensive intervention and hypothetical scenarios of 
treatment and risk behavior simultaneously. The model suggested that 
intensive intervention would considerably reduce incidence over the 
intervention period, but if after intensive intervention treatment was deferred in 
line with reimbursement regulations, this benefit would dissipate in the long-
term. Interestingly, even though high treatment rates after intensive 
intervention led to nearly the same simulated prevalence with or without 
intensive intervention in the long-term, intensive intervention was predicted to 
save treatment costs 46. As a consequence of the model projections, the 
HCVree trial was extended until the end of 2017. New incident infections as 
well as reinfections will be treated during this period.   
 
Additionally, reimbursement regulations for DAA-based HCV therapy changed 
in May 2017, and  DAA therapy is now reimbursed irrespective of fibrosis 
stage in all HIV+ patients. We therefore expect trends in risk behavior to 
shape the future course of HCV transmission among HIV+ MSM in 
Switzerland, making behavioral interventions such as the Swiss HCVree trial 
even more critical.  
 
Other interventions to prevent infection/reinfection among MSM: 
In addition to behavioral interventions addressing inconsistent condom use 
among MSM at risk for HCV infection/reinfection (such as the Swiss HCVree 
trial), effective behavioral interventions targeting other HCV-related risks 
among MSM are urgently required.  
 
Traditional harm reduction interventions targeting MSM who inject drugs: 
There is mounting evidence that traditional harm reduction interventions such 
as opiate substitution therapy (OST) and high coverage needle and syringe 
programs (NSP) are effective at reducing HCV transmission among people 
who inject drugs. A recent Cochrane review and meta-analysis found that 
OST reduce the risk of acquiring HCV by 50% (RR=0.50, 95% CI: 0.40-0.63) 
47.  In addition, high NSP coverage was found to reduce HCV acquisition by 
23% (RR=0.77, 95% CI: 0.38-1.54) 47, with higher impact seen in Europe 
(RR=0.44, 95% CI: 0.24-0.80) 47. When combining high coverage of both NSP 
and OST interventions, the risk of acquiring HCV was reduced by an 
estimated 71% (RR=0.29, 95% CI: 0.13-0.65) 47. Despite this evidence, the 
impact of harm reduction among MSM who inject drugs has not been studied 
specifically. Additionally, MSM who inject drugs may not self-identify as 
people who inject drugs, and therefore may not access traditional harm 
reduction services.  
 
Adapted HIV prevention interventions among MSM: It is unclear whether 
interventions to prevent HIV transmission among MSM would be effective to 
prevent HCV infection among MSM. However, given potential shared 
transmission routes it is possible these interventions could be used or 
adapted. There is an extensive body of literature on behavioral interventions 
to reduce unprotected anal intercourse and HIV transmission among MSM48. 
For example, a Cochrane review and meta-analysis of 40 behavioral 
interventions found a reduction of occasions of or partners for unprotected 
anal sex by 27% (95%CI 15%-37%) compared to no or minimal intervention48. 
One intervention, Project ECHO, targets substance using MSM and uses 
Personalized Cognitive Counseling to help participants identify and avoid risky 
sexual and drug using behaviors49. Among HIV-negative MSM who reported 
sex after substance use in the past 6 months, Project ECHO reduced the 
number of condomless anal intercourse events with non-primary partners by 
46% (RR = 0.56; 95% CI 0.34 - 0.92) compared to the control group49.  
Studies exploring whether interventions similar to or adapted from Project 
ECHO are effective for HCV prevention among MSM are warranted. 
 
Chemsex intervention: There is an emerging body of literature examining the 
development of educational and counseling interventions targeted at MSM 
who use crystal methamphetamine with sex (“ChemSex”) 50-52, which may 
reduce the risk of acquiring HCV among this population. ChemSex is 
associated with HCV infection, as well as high risk behaviors such as multiple 
sexual partners, transactional sex, group sex, fisting, sharing sex toys, 
injecting drug use, higher alcohol consumption and the use of ‘bareback’ 
sexual networking applications53.  
 
In one HIV/GUM clinic in London, following completion of HCV treatment, 
clinicians provide MSM with harm reduction messages, education on HCV 
transmission risks related to ChemSex, ChemSex packs including safe 
injecting equipment and educational information and referal to on-site, 
ChemSex behaviour change support 52. It has been reported that ChemSex 
motivations are often associated with internalized homophobia and shame 
surrounding homosexual sex, gay cultural/societal norms, sexual performance 
anxieties, and body image concerns. Successful behavioral interventions for 
MSM at risk of acquiring/transmitting HCV in ChemSex environments would 
need to address these sensitive issues.  
 
Conclusion 
HCV reinfection rates among MSM are high (3-15 per 100 person-years), and 
are 3-10 fold higher than rates of primary incidence, indicating a high-risk core 
group of MSM at risk for HCV infection and reinfection. Factors associated 
with HCV infection among MSM point towards a number of varied sexual and 
drug-related risks, which could be targeted for interventions to prevent 
infection/reinfection. Modeling indicates that tackling increasing incidence and 
high reinfection rates requires high levels of HCV treatment combined with 
behavioral interventions. Enhanced testing strategies and prompt retreating of 
reinfection may be required to promptly diagnosed reinfections and prevent 
further onwards transmissions. Others have suggested strategies such as 
home-based dried blot spot collection at fixed time points or after a risk event.  
Behavioral interventions studies addressing HCV reinfection are required, 
such as the HCVree trial in Switzerland. Other relevant interventions may 
include traditional harm reduction interventions targeting MSM who inject 
drugs, adapted behavioral interventions targeting HIV risks among substance 
using populations, and interventions to prevent harms related to chemsex and 
other risk associated with drug use with or before sexual episodes.  It is likely 
that a suite of interventions targeting different sub-subpopulations and risks 
among MSM will be required, instead of one blanket intervention. 
  
 Centre Incidence 
reinfections/100py 
(95% CI) 
Number of 
reinfections 
Person years 
follow up 
Dusseldorf (n=59) 8.1 (4.6-14.3) 12 148 
Hamburg (n=73) 5.0 (2.9-8.7) 13 258 
Berlin (n=95) 8.2 (5.6-12.1) 26 316 
Bonn (n=11) 4.8 (0.7-33.7) 1 21 
London – Chelwest 
(n=190) 
7.0 (5.3-9.1) 52 746 
London – Royal 
Free (n=69) 
5.7 (3.7-8.7) 21 369 
Paris (n=27) 21.8 (11.3-41.8) 9 41 
Vienna (n=28) 16.8 (8.7-32.3) 9 54 
 
Table 1. HCV reinfection incidence among HIV+ MSM in Europe. From 
Ingilitz et al.17. 
 
 
  
FIGURE LEGENDS 
 
FIGURE 1. HCV reinfection incidence after successful treatment among 
HIV+ MSM as reported in Amsterdam, London, the NEAT cohort, and 
San Diego, California 17-20. 
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